Johnson & Johnson (JNJ) 98.28 $JNJ
J&J Snack Foods posts 3Q profit
Automated Insights - Mon Jul 27, 3:07PM CDT
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Monday reported fiscal third-quarter net income of $24.5 million.
JNJ: 98.28 (-0.87), JJSF: 110.79 (+0.83)
Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 10:20AM CDT
We expect PerkinElmer Inc. (VAR) to beat the Zacks Consensus Estimate when it reports second-quarter 2015 results on Jul 29.
JNJ: 98.28 (-0.87), LDRH: 45.25 (+0.24), AMAG: 65.07 (-5.37), PKI: 50.43 (-0.46)
Acidity Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zs3x7/acidity_global) has announced the addition of the "Acidity Global Clinical Trials Review, H1, 2015" report to their offering. "Acidity Global Clinical Trials Review, H1, 2015" provides data on the Acidity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acidity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acidity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Acidity Therapeutics Clinical Trials - Dr. Reddy's Laboratories Limited - Merck & Co., Inc. - Johnson & Johnson - Pozen, Inc. - Emcure Pharmaceuticals Ltd. - Eisai Co., Ltd. - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - AstraZeneca PLC - Abbott Laboratories - Academic Medical Center - Central Council for Research in Unani Medicine - Changhai Hospital - Gujarat Ayurved University - Tehran University of Medical Sciences - University Hospital Koge For more information visit http://www.researchandmarkets.com/research/3z...ity_global
JNJ: 98.28 (-0.87), ABT: 50.69 (-0.36), MRK: 56.99 (-0.42), AZN: 32.71 (-33.05), POZN: 12.02 (+0.47)
Appendicitis Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzv2k/appendicitis) has announced the addition of the "Appendicitis Global Clinical Trials Review, H1, 2015" report to their offering. "Appendicitis Global Clinical Trials Review, H1, 2015" provides data on the Appendicitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Appendicitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Appendicitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Appendicitis Therapeutics Clinical Trials - Johnson & Johnson - Pfizer Inc. - The Children's Mercy Hospital - University of California, San Diego - Academic Medical Center - HaEmek Medical Center - Karolinska University Hospital - Kashan University of Medical Sciences and Health Services - Nationwide Children's Hospital - Assistance Publique - Hopitaux de Paris - Centre Hospitalier Universitaire de Nantes - Centre Hospitalier Universitaire, Amiens For more information visit http://www.researchandmarkets.com/research/lt...pendicitis
JNJ: 98.28 (-0.87), PFE: 34.34 (+0.08)
Complex Regional Pain Syndrome - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwct8h/complex_regional) has announced the addition of the "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Complex Regional Pain Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Complex Regional Pain Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Complex Regional Pain Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Complex Regional Pain Syndrome Therapeutics Clinical Trials - Johnson & Johnson - Celgene Corporation - Endo International plc - Leiden University Medical Center - Academic Hospital Maastricht - Massachusetts General Hospital - Mayo Clinic - Medical University of Vienna - Aalto University School of Science and Technology - Centre Hospitalier Universitaire, Amiens - Charite - Universitatsmedizin Berlin - Danish Pain Research Center - Drexel University College of Medicine For more information visit http://www.researchandmarkets.com/research/vw...x_regional
JNJ: 98.28 (-0.87), CELGZ: 2.00 (-0.06)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 6.91 (-0.05), SNN: 34.75 (-0.31), JNJ: 98.28 (-0.87), MMM: 148.71 (-0.62), OSIR: 21.72 (unch), MDXG: 12.54 (+0.20), NVDQ: 12.13 (-0.30)
Global Cosmetics Market 2015-2020: Market was $460 Billion in 2014 and is Estimated to Reach $675 Billion by 2020
M2 - Mon Jul 27, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgszcl/global_cosmetics) has announced the addition of the "Global Cosmetics Market - By Product type, Ingredient, Geography, And Vendors - Market Size, Demand Forecasts, Industry Trends and Updates, Supplier Market Shares 2014- 2020" report to their offering. The global Cosmetic market was 460 billion USD in 2014 and is estimated to reach 675 billion USD by 2020 growing at a rate of 6.4%. Of the cosmetic products, Skin care has the highest market share while Oral Cosmetics would be the fasted growing market during the forecasted period. Growth by Region: APAC leads the cosmetic industry with a market share of 35% in 2014, followed by Western Europe and North America. The high market share of Asia Pacific region is attributed to the fact that customers are relatively beauty conscious. Moreover, with the expected growth rate being highest among all regions, APAC is the region of focus for the cosmetics providers. Drivers vs. Constraints: - E-Retail / Online Shopping - Rise in disposable income - Travel Retail - Product Innovation - Consumer perception of the products causing side effects - Unregulated market The sale of cosmetics is seeing a shift from being traditionally purchased to buying online. Moreover, increase in spending income, especially in the developing countries is driving the market. In addition to the above factors, other factors acting as drivers/constraints to the industry are available in the report along with a detailed description of their impact on the market. Industry Trends and Updates: - Product Innovations Companies are focusing on bringing in products specific to the consumer requirement. Gender specific products are also increasing at a rapid pace. - Organic products Growing concerns on the long term effects due to usage of cosmetics is forcing the companies to bring in organic products as well. This market is expected to increase during the forecasted period - Focus on Packaging Cosmetics Manufacturers profiling: The report also provides supplier intelligence which includes information such as top players in the industry (Procter and Gamble, Johnson and Johnson, L'Oreal, Avon, Henkel, Estee Lauder, etc among others). This also gives information on the supplier's market share, competitive landscape as well. Key Topics Covered: 1. Introduction - Research Methodology 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Cosmetics Market Segmentation, Forecasts and Trends - by Volume, by Revenue 6. Global Vendor Market Share Analysis 7. Competitive Intelligence - Company Profiles 8. Investment Analysis 9. Future of Cosmetics Market Companies Mentioned - Avon - Bayer - Clarins - Estee Lauder - Henkel - Hindistan Unilever - Johnson and Johnson - L'Oreal - Procter and Gamble For more information visit http://www.researchandmarkets.com/research/jg..._cosmetics
JNJ: 98.28 (-0.87), EL: 86.87 (-1.53)
4 Great Stocks For Beginners
Matthew Frankel, The Motley Fool - Motley Fool - Sun Jul 26, 7:09AM CDT
If you're new to the stock market, it may be tempting to pour your money into "it" stocks like Netflix , Tesla , and Amazon.com . However, that's the exact opposite of what you should be doing. Instead, the primary objective of a new investor...
JNJ: 98.28 (-0.87), XOM: 79.26 (-0.68), CL: 67.30 (+0.30)
Is Bristol-Myers Squibb Outpacing Johnson & Johnson?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 25, 9:03AM CDT
Source: Flickr user Paul A race for dominance in the anticoagulant market is heating up between Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) with the winner standing to reap billions of dollars in additional revenue...
JNJ: 98.28 (-0.87), BMY: 64.30 (-1.68)
A look at the largest companies in the S&P 500
By The Associated Press - AP - Fri Jul 24, 6:08PM CDT
Amazon surpassed the world's largest retailer, Wal-Mart Stores Inc., in market value Friday, on the back of a strong earnings report. Amazon shares closed up nearly 10 percent, giving the Seattle company a market value of $247.77 billion, versus $230.53 billion for Wal-Mart.
AMZN: 531.41 (+1.99), GE: 25.95 (+0.20), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), DIS: 118.25 (-0.66), WMT: 71.38 (-0.20), XOM: 79.26 (-0.68), BAC: 17.67 (-0.23), WFC: 57.59 (-0.19), GOOG: 627.26 (+3.70), JNJ: 98.28 (-0.87), GOOGL: 658.27 (+3.50), PG: 79.97 (-0.32), MSFT: 45.35 (-0.59), AAPL: 122.77 (-1.73)
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
By LINDA A. JOHNSON - AP - Fri Jul 24, 4:57PM CDT
TRENTON, N.J. (AP) — An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely costly — for patients with the liver-destroying virus.
JNJ: 98.28 (-0.87), GILD: 110.54 (-2.29), MRK: 56.99 (-0.42), BMY: 64.30 (-1.68)
After Yesterday's Decline of 1.04%, Johnson & Johnson Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jul 24, 4:56PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.05 to a high of $99.95. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $99.73 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 98.28 (-0.87)
Johnson & Johnson Set to Possibly Rebound After Yesterday's Selloff of 1.04%
Comtex SmarTrend(R) - Fri Jul 24, 4:55PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.05 to a high of $99.95. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $99.73 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 98.28 (-0.87)
Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed
at Investor's Business Daily - Fri Jul 24, 10:44AM CDT
Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its...
JNJ: 98.28 (-0.87), BIIB: 309.43 (+9.40), ABBV: 69.34 (+1.26)
Global Wound Care Markets 2015
M2 - Fri Jul 24, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pcf98/global_wound_care) has announced the addition of the "Global Wound Care Markets (Twelve Country Analysis: Germany, France, Italy, United Kingdom, United States, Japan, Canada, China, India, Brazil, Australia, South Korea)" report to their offering. The report provides a competitive market summary. The wound care market is varied in terms of both product offerings and product maturity. Several of the products within the global wound care market are mature, such as anti-infectives and pressure relief devices, while others such as biological dressings and negative pressure wound therapy are in the infant stages of development. Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth during the forecast period. Another area driving growth is that of negative pressure wound therapy. The wound care industry is an incredibly diverse and highly competitive arena that is ever-changing. Kalorama Information feels that the market will continue to expand over the long term due to an aging population, longer life expectancies, and an increasing number of sicker patients across all care settings. In the short term, there will be more ebb and flow in the industry due to changes in reimbursement, contract bidding, mergers and acquisitions, and changes in the delivery of health care. Patients have more complex coexisting illnesses such as diabetes, heart failure, obesity, pulmonary and vascular diseases, immobility issues and chronic wounds. These factors are all influenced by future demographic trends, economic uncertainty, the impact of health care reform, increasing numbers of uninsured patients, reimbursement pressures from third party payers, continuing shortage of nurses and physicians and increasing technology and supply costs. Profiles of the major companies in the wound care market are provided: - Johnson & Johnson - Medtronic plc - Kinetic Concepts, Inc (Acelity) - Hill-Rom - Smith and Nephew, PLC - 3M Health Care - M?lnlycke Health Care - Aesculap/B. Braun - ConvaTec, Ltd. - Baxter BioScience - Paul Hartmann AG Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION THREE: TWELVE COUNTRY WOUND CARE MARKET SIZE AND FORECAST FOUR: COMPANY PROFILES For more information visit http://www.researchandmarkets.com/research/8p...wound_care
SNN: 34.75 (-0.31), JNJ: 98.28 (-0.87), MDT: 75.66 (-0.35)
Advanced Remote Patient Monitoring Systems Market Report, 2015 Edition
M2 - Fri Jul 24, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3x94gc/advanced_remote) has announced the addition of the "Advanced Remote Patient Monitoring Systems, 8th Edition" report to their offering. New patient monitoring systems are emerging in response to the increased healthcare needs of an aging population, new wireless technologies, better video and monitoring technologies, decreasing healthcare resources, an emphasis on reducing hospital days, and proven cost-effectiveness. Advanced Remote Patient Monitoring Systems, in its eighth edition, is a comprehensive study on the patient monitoring industry, including patient monitoring equipment and devices which have advanced features. The report specifically focuses on technologically advanced (including wireless and remote) patient monitors; monitors with patient data processing applications; and monitors which are capable of data transfer to an EMR system-including equipment and peripherals which coordinate the flow of data to hospital electronic medical record systems. This report provides complete market sizes and forecasts for the important segments of the advanced monitoring market: - Blood Management and Function Monitors (Glucose Monitors, Blood Pressure Monitors, PT/INR Monitors, Other Monitors) - Cardiac Event and Function Monitors (Cardiac Rhythm/Event Monitors, EKG/ECG, Fetal Heart, Other Monitors) - Neurological Event Monitors (EEG, Other Equipment) - Respiratory Function Monitors (Anesthesia Monitors, Capnographs, Pulse Oximeters, Sleep Monitors, Spirometers) - Other Advanced Monitors Key Topics Covered: One: Executive Summary Two: Introduction Three: Advanced Patient Monitoring Products And Technologies Four: Competitor Trends And Market Share Analysis Five: Market Trends & Indicators Six: Global Market Size And Forecast Seven: Global Markets: Regional Analysis Regional Market Summary Eight: Corporate Profiles - Abbott - Aerotel Medical Systems - Alere, Inc. - AMD Global Telemedicine - American TeleCare - AuthentiDate Holding Corporation - B.Braun Melsungen AG - Baxter International - BioTelemetry, Inc. - Biotronik - Bosch Healthcare - Boston Scientific - Cardiocom, LLC. - Carematix, Inc. - Compumedics, Ltd. - CONMED Corporation - C.R. Bard, Inc. - Criticare Systems, Inc. - Dexcom, Inc. - Draeger Medical - Fukuda Denshi Co. - GE Healthcare - Getinge Group - GlobalMed Group - Hoana Medical, Inc. - Honeywell HomMed - Infinium Medical, Inc. - Insulet - InTechnology plc - Intel Corporation - InTouch Health - Johnson & Johnson - LifeWatch Technologies - Masimo Corporation - Medtronic For more information visit http://www.researchandmarkets.com/research/3x...ced_remote
MASI: 41.09 (-0.89), BCR: 190.14 (+2.39), MDT: 75.66 (-0.35), HON: 101.64 (-1.13), MDSY: 1.50 (-0.02), ALR: 50.04 (-0.89), INTC: 28.35 (+0.29), BSX: 17.11 (-0.25), CMD: 106.96 (+3.10), JNJ: 98.28 (-0.87), BAX: 37.70 (+0.06), BEAT: 11.10 (+0.01), CNMD: 57.32 (-0.38), ADAT: 0.14 (unch)
'Twilight' Was Right: Vampire Trading Can Make You Rich
at The Street - Fri Jul 24, 6:37AM CDT
New research says trading after the market closes is about twice as profitable as long-term market returns. The problem? It's for night owls.
TSLA: 253.01 (-12.40), JNJ: 98.28 (-0.87), IBM: 159.07 (-0.68), FB: 94.17 (-2.78), PG: 79.97 (-0.32), AAPL: 122.77 (-1.73)
Morcellator Wrongful Death Suit Settlement Announced, Says Legal-Bay
PR Newswire - Fri Jul 24, 4:00AM CDT
Legal-Bay LLC, the Lawsuit Settlement Funding Company, announced today that LiNA Medical has settled a case against them for an undisclosed amount over a power morcellator death case. The company settled the case before it even went to trial, and there are approximately 20 other morcellator lawsuits at this time. According to Drug Watch, the company did not comment on the settlement. This case was one of the first laparoscopic power morcellator lawsuits filed in federal court, and according to the U.S. FDA, as many as 1 in 350 women are "suspected of having undiagnosed uterine sarcoma that may be spread during morcellation." The victim's husband filed the suit, stating she had no evidence of cancer or disease prior to her surgery in March of 2012, however, about a week after she had the procedure, doctors told her she had cancer, and she died at 53 - only 11 months after the surgery. Johnson & Johnson's Ethicon unit and Blue Endo were also named in the lawsuit which was filed in the U.S. District Court for the Eastern District of Pennsylvania, claiming they failed to warn about the possible risk of the spread of undiagnosed cancer, however there has been no report that either J&J or Blue Endo settled their portion of the claims.
JNJ: 98.28 (-0.87)
Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jul 23, 4:48PM CDT
Investor focus this quarter will remain on AbbVie's (ABBV) Humira, Viekira and Imbruvica.
CYTK: 7.19 (+0.06), JNJ: 98.28 (-0.87), MDCO: 33.39 (-0.43), ABBV: 69.34 (+1.26)
Critical Alerts For Juno Therapeutics Inc, Whiting Petroleum, Johnson & Johnson, Windstream and Whirlpool Released By InvestorsObserver
PR Newswire - Thu Jul 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JUNO, WLL, JNJ, WIN and WHR.
WHR: 171.84 (-4.26), JNJ: 98.28 (-0.87), WLL: 21.13 (-1.80), JUNO: 47.80 (-2.36), WIN: 4.70 (+0.13)
J&J Snack Foods posts 3Q profit
Automated Insights - Mon Jul 27, 3:07PM CDT
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Monday reported fiscal third-quarter net income of $24.5 million.
JNJ: 98.28 (-0.87), JJSF: 110.79 (+0.83)
Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 10:20AM CDT
We expect PerkinElmer Inc. (VAR) to beat the Zacks Consensus Estimate when it reports second-quarter 2015 results on Jul 29.
JNJ: 98.28 (-0.87), LDRH: 45.25 (+0.24), AMAG: 65.07 (-5.37), PKI: 50.43 (-0.46)
Acidity Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zs3x7/acidity_global) has announced the addition of the "Acidity Global Clinical Trials Review, H1, 2015" report to their offering. "Acidity Global Clinical Trials Review, H1, 2015" provides data on the Acidity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acidity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acidity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Acidity Therapeutics Clinical Trials - Dr. Reddy's Laboratories Limited - Merck & Co., Inc. - Johnson & Johnson - Pozen, Inc. - Emcure Pharmaceuticals Ltd. - Eisai Co., Ltd. - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - AstraZeneca PLC - Abbott Laboratories - Academic Medical Center - Central Council for Research in Unani Medicine - Changhai Hospital - Gujarat Ayurved University - Tehran University of Medical Sciences - University Hospital Koge For more information visit http://www.researchandmarkets.com/research/3z...ity_global
JNJ: 98.28 (-0.87), ABT: 50.69 (-0.36), MRK: 56.99 (-0.42), AZN: 32.71 (-33.05), POZN: 12.02 (+0.47)
Appendicitis Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzv2k/appendicitis) has announced the addition of the "Appendicitis Global Clinical Trials Review, H1, 2015" report to their offering. "Appendicitis Global Clinical Trials Review, H1, 2015" provides data on the Appendicitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Appendicitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Appendicitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Appendicitis Therapeutics Clinical Trials - Johnson & Johnson - Pfizer Inc. - The Children's Mercy Hospital - University of California, San Diego - Academic Medical Center - HaEmek Medical Center - Karolinska University Hospital - Kashan University of Medical Sciences and Health Services - Nationwide Children's Hospital - Assistance Publique - Hopitaux de Paris - Centre Hospitalier Universitaire de Nantes - Centre Hospitalier Universitaire, Amiens For more information visit http://www.researchandmarkets.com/research/lt...pendicitis
JNJ: 98.28 (-0.87), PFE: 34.34 (+0.08)
Complex Regional Pain Syndrome - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwct8h/complex_regional) has announced the addition of the "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Complex Regional Pain Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Complex Regional Pain Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Complex Regional Pain Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Complex Regional Pain Syndrome Therapeutics Clinical Trials - Johnson & Johnson - Celgene Corporation - Endo International plc - Leiden University Medical Center - Academic Hospital Maastricht - Massachusetts General Hospital - Mayo Clinic - Medical University of Vienna - Aalto University School of Science and Technology - Centre Hospitalier Universitaire, Amiens - Charite - Universitatsmedizin Berlin - Danish Pain Research Center - Drexel University College of Medicine For more information visit http://www.researchandmarkets.com/research/vw...x_regional
JNJ: 98.28 (-0.87), CELGZ: 2.00 (-0.06)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 6.91 (-0.05), SNN: 34.75 (-0.31), JNJ: 98.28 (-0.87), MMM: 148.71 (-0.62), OSIR: 21.72 (unch), MDXG: 12.54 (+0.20), NVDQ: 12.13 (-0.30)
Global Cosmetics Market 2015-2020: Market was $460 Billion in 2014 and is Estimated to Reach $675 Billion by 2020
M2 - Mon Jul 27, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgszcl/global_cosmetics) has announced the addition of the "Global Cosmetics Market - By Product type, Ingredient, Geography, And Vendors - Market Size, Demand Forecasts, Industry Trends and Updates, Supplier Market Shares 2014- 2020" report to their offering. The global Cosmetic market was 460 billion USD in 2014 and is estimated to reach 675 billion USD by 2020 growing at a rate of 6.4%. Of the cosmetic products, Skin care has the highest market share while Oral Cosmetics would be the fasted growing market during the forecasted period. Growth by Region: APAC leads the cosmetic industry with a market share of 35% in 2014, followed by Western Europe and North America. The high market share of Asia Pacific region is attributed to the fact that customers are relatively beauty conscious. Moreover, with the expected growth rate being highest among all regions, APAC is the region of focus for the cosmetics providers. Drivers vs. Constraints: - E-Retail / Online Shopping - Rise in disposable income - Travel Retail - Product Innovation - Consumer perception of the products causing side effects - Unregulated market The sale of cosmetics is seeing a shift from being traditionally purchased to buying online. Moreover, increase in spending income, especially in the developing countries is driving the market. In addition to the above factors, other factors acting as drivers/constraints to the industry are available in the report along with a detailed description of their impact on the market. Industry Trends and Updates: - Product Innovations Companies are focusing on bringing in products specific to the consumer requirement. Gender specific products are also increasing at a rapid pace. - Organic products Growing concerns on the long term effects due to usage of cosmetics is forcing the companies to bring in organic products as well. This market is expected to increase during the forecasted period - Focus on Packaging Cosmetics Manufacturers profiling: The report also provides supplier intelligence which includes information such as top players in the industry (Procter and Gamble, Johnson and Johnson, L'Oreal, Avon, Henkel, Estee Lauder, etc among others). This also gives information on the supplier's market share, competitive landscape as well. Key Topics Covered: 1. Introduction - Research Methodology 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Cosmetics Market Segmentation, Forecasts and Trends - by Volume, by Revenue 6. Global Vendor Market Share Analysis 7. Competitive Intelligence - Company Profiles 8. Investment Analysis 9. Future of Cosmetics Market Companies Mentioned - Avon - Bayer - Clarins - Estee Lauder - Henkel - Hindistan Unilever - Johnson and Johnson - L'Oreal - Procter and Gamble For more information visit http://www.researchandmarkets.com/research/jg..._cosmetics
JNJ: 98.28 (-0.87), EL: 86.87 (-1.53)
4 Great Stocks For Beginners
Matthew Frankel, The Motley Fool - Motley Fool - Sun Jul 26, 7:09AM CDT
If you're new to the stock market, it may be tempting to pour your money into "it" stocks like Netflix , Tesla , and Amazon.com . However, that's the exact opposite of what you should be doing. Instead, the primary objective of a new investor...
JNJ: 98.28 (-0.87), XOM: 79.26 (-0.68), CL: 67.30 (+0.30)
Is Bristol-Myers Squibb Outpacing Johnson & Johnson?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 25, 9:03AM CDT
Source: Flickr user Paul A race for dominance in the anticoagulant market is heating up between Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) with the winner standing to reap billions of dollars in additional revenue...
JNJ: 98.28 (-0.87), BMY: 64.30 (-1.68)
A look at the largest companies in the S&P 500
By The Associated Press - AP - Fri Jul 24, 6:08PM CDT
Amazon surpassed the world's largest retailer, Wal-Mart Stores Inc., in market value Friday, on the back of a strong earnings report. Amazon shares closed up nearly 10 percent, giving the Seattle company a market value of $247.77 billion, versus $230.53 billion for Wal-Mart.
AMZN: 531.41 (+1.99), GE: 25.95 (+0.20), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), DIS: 118.25 (-0.66), WMT: 71.38 (-0.20), XOM: 79.26 (-0.68), BAC: 17.67 (-0.23), WFC: 57.59 (-0.19), GOOG: 627.26 (+3.70), JNJ: 98.28 (-0.87), GOOGL: 658.27 (+3.50), PG: 79.97 (-0.32), MSFT: 45.35 (-0.59), AAPL: 122.77 (-1.73)
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
By LINDA A. JOHNSON - AP - Fri Jul 24, 4:57PM CDT
TRENTON, N.J. (AP) — An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely costly — for patients with the liver-destroying virus.
JNJ: 98.28 (-0.87), GILD: 110.54 (-2.29), MRK: 56.99 (-0.42), BMY: 64.30 (-1.68)
After Yesterday's Decline of 1.04%, Johnson & Johnson Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jul 24, 4:56PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.05 to a high of $99.95. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $99.73 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 98.28 (-0.87)
Johnson & Johnson Set to Possibly Rebound After Yesterday's Selloff of 1.04%
Comtex SmarTrend(R) - Fri Jul 24, 4:55PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.05 to a high of $99.95. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $99.73 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 98.28 (-0.87)
Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed
at Investor's Business Daily - Fri Jul 24, 10:44AM CDT
Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its...
JNJ: 98.28 (-0.87), BIIB: 309.43 (+9.40), ABBV: 69.34 (+1.26)
Global Wound Care Markets 2015
M2 - Fri Jul 24, 9:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pcf98/global_wound_care) has announced the addition of the "Global Wound Care Markets (Twelve Country Analysis: Germany, France, Italy, United Kingdom, United States, Japan, Canada, China, India, Brazil, Australia, South Korea)" report to their offering. The report provides a competitive market summary. The wound care market is varied in terms of both product offerings and product maturity. Several of the products within the global wound care market are mature, such as anti-infectives and pressure relief devices, while others such as biological dressings and negative pressure wound therapy are in the infant stages of development. Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth during the forecast period. Another area driving growth is that of negative pressure wound therapy. The wound care industry is an incredibly diverse and highly competitive arena that is ever-changing. Kalorama Information feels that the market will continue to expand over the long term due to an aging population, longer life expectancies, and an increasing number of sicker patients across all care settings. In the short term, there will be more ebb and flow in the industry due to changes in reimbursement, contract bidding, mergers and acquisitions, and changes in the delivery of health care. Patients have more complex coexisting illnesses such as diabetes, heart failure, obesity, pulmonary and vascular diseases, immobility issues and chronic wounds. These factors are all influenced by future demographic trends, economic uncertainty, the impact of health care reform, increasing numbers of uninsured patients, reimbursement pressures from third party payers, continuing shortage of nurses and physicians and increasing technology and supply costs. Profiles of the major companies in the wound care market are provided: - Johnson & Johnson - Medtronic plc - Kinetic Concepts, Inc (Acelity) - Hill-Rom - Smith and Nephew, PLC - 3M Health Care - M?lnlycke Health Care - Aesculap/B. Braun - ConvaTec, Ltd. - Baxter BioScience - Paul Hartmann AG Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION THREE: TWELVE COUNTRY WOUND CARE MARKET SIZE AND FORECAST FOUR: COMPANY PROFILES For more information visit http://www.researchandmarkets.com/research/8p...wound_care
SNN: 34.75 (-0.31), JNJ: 98.28 (-0.87), MDT: 75.66 (-0.35)
Advanced Remote Patient Monitoring Systems Market Report, 2015 Edition
M2 - Fri Jul 24, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3x94gc/advanced_remote) has announced the addition of the "Advanced Remote Patient Monitoring Systems, 8th Edition" report to their offering. New patient monitoring systems are emerging in response to the increased healthcare needs of an aging population, new wireless technologies, better video and monitoring technologies, decreasing healthcare resources, an emphasis on reducing hospital days, and proven cost-effectiveness. Advanced Remote Patient Monitoring Systems, in its eighth edition, is a comprehensive study on the patient monitoring industry, including patient monitoring equipment and devices which have advanced features. The report specifically focuses on technologically advanced (including wireless and remote) patient monitors; monitors with patient data processing applications; and monitors which are capable of data transfer to an EMR system-including equipment and peripherals which coordinate the flow of data to hospital electronic medical record systems. This report provides complete market sizes and forecasts for the important segments of the advanced monitoring market: - Blood Management and Function Monitors (Glucose Monitors, Blood Pressure Monitors, PT/INR Monitors, Other Monitors) - Cardiac Event and Function Monitors (Cardiac Rhythm/Event Monitors, EKG/ECG, Fetal Heart, Other Monitors) - Neurological Event Monitors (EEG, Other Equipment) - Respiratory Function Monitors (Anesthesia Monitors, Capnographs, Pulse Oximeters, Sleep Monitors, Spirometers) - Other Advanced Monitors Key Topics Covered: One: Executive Summary Two: Introduction Three: Advanced Patient Monitoring Products And Technologies Four: Competitor Trends And Market Share Analysis Five: Market Trends & Indicators Six: Global Market Size And Forecast Seven: Global Markets: Regional Analysis Regional Market Summary Eight: Corporate Profiles - Abbott - Aerotel Medical Systems - Alere, Inc. - AMD Global Telemedicine - American TeleCare - AuthentiDate Holding Corporation - B.Braun Melsungen AG - Baxter International - BioTelemetry, Inc. - Biotronik - Bosch Healthcare - Boston Scientific - Cardiocom, LLC. - Carematix, Inc. - Compumedics, Ltd. - CONMED Corporation - C.R. Bard, Inc. - Criticare Systems, Inc. - Dexcom, Inc. - Draeger Medical - Fukuda Denshi Co. - GE Healthcare - Getinge Group - GlobalMed Group - Hoana Medical, Inc. - Honeywell HomMed - Infinium Medical, Inc. - Insulet - InTechnology plc - Intel Corporation - InTouch Health - Johnson & Johnson - LifeWatch Technologies - Masimo Corporation - Medtronic For more information visit http://www.researchandmarkets.com/research/3x...ced_remote
MASI: 41.09 (-0.89), BCR: 190.14 (+2.39), MDT: 75.66 (-0.35), HON: 101.64 (-1.13), MDSY: 1.50 (-0.02), ALR: 50.04 (-0.89), INTC: 28.35 (+0.29), BSX: 17.11 (-0.25), CMD: 106.96 (+3.10), JNJ: 98.28 (-0.87), BAX: 37.70 (+0.06), BEAT: 11.10 (+0.01), CNMD: 57.32 (-0.38), ADAT: 0.14 (unch)
'Twilight' Was Right: Vampire Trading Can Make You Rich
at The Street - Fri Jul 24, 6:37AM CDT
New research says trading after the market closes is about twice as profitable as long-term market returns. The problem? It's for night owls.
TSLA: 253.01 (-12.40), JNJ: 98.28 (-0.87), IBM: 159.07 (-0.68), FB: 94.17 (-2.78), PG: 79.97 (-0.32), AAPL: 122.77 (-1.73)
Morcellator Wrongful Death Suit Settlement Announced, Says Legal-Bay
PR Newswire - Fri Jul 24, 4:00AM CDT
Legal-Bay LLC, the Lawsuit Settlement Funding Company, announced today that LiNA Medical has settled a case against them for an undisclosed amount over a power morcellator death case. The company settled the case before it even went to trial, and there are approximately 20 other morcellator lawsuits at this time. According to Drug Watch, the company did not comment on the settlement. This case was one of the first laparoscopic power morcellator lawsuits filed in federal court, and according to the U.S. FDA, as many as 1 in 350 women are "suspected of having undiagnosed uterine sarcoma that may be spread during morcellation." The victim's husband filed the suit, stating she had no evidence of cancer or disease prior to her surgery in March of 2012, however, about a week after she had the procedure, doctors told her she had cancer, and she died at 53 - only 11 months after the surgery. Johnson & Johnson's Ethicon unit and Blue Endo were also named in the lawsuit which was filed in the U.S. District Court for the Eastern District of Pennsylvania, claiming they failed to warn about the possible risk of the spread of undiagnosed cancer, however there has been no report that either J&J or Blue Endo settled their portion of the claims.
JNJ: 98.28 (-0.87)
Will AbbVie (ABBV) Surprise on Earnings Again in Q2? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jul 23, 4:48PM CDT
Investor focus this quarter will remain on AbbVie's (ABBV) Humira, Viekira and Imbruvica.
CYTK: 7.19 (+0.06), JNJ: 98.28 (-0.87), MDCO: 33.39 (-0.43), ABBV: 69.34 (+1.26)
Critical Alerts For Juno Therapeutics Inc, Whiting Petroleum, Johnson & Johnson, Windstream and Whirlpool Released By InvestorsObserver
PR Newswire - Thu Jul 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for JUNO, WLL, JNJ, WIN and WHR.
WHR: 171.84 (-4.26), JNJ: 98.28 (-0.87), WLL: 21.13 (-1.80), JUNO: 47.80 (-2.36), WIN: 4.70 (+0.13)
